Ocular Therapeutix (OCUL) has released an update.
Ocular Therapeutix, Inc. announced an FDA-approved modification to the Special Protocol Assessment for their Phase 3 SOL trial of AXPAXLI for treating wet age-related macular degeneration. This modification permits the inclusion of treatment-naïve subjects with certain visual acuity standards and introduces a new trial condition involving an optimized axitinib intravitreal implant designed for improved drug release synchronization with hydrogel bioresorption.
For further insights into OCUL stock, check out TipRanks’ Stock Analysis page.
